Showing 225 results

Filters Content type: News, Editors' picks Topic: Injectable & long-acting HIV treatment

Research into injectable medications and other innovative forms of HIV treatment. It is hoped that they may only need to be taken every few weeks or months, rather than daily.

 

New & experimental HIV treatments

Ibalizumab monoclonal antibody is effective in real-world use

News
7 October 2019
Injectable & long-acting HIV treatment

Women Find Long-Acting Injectable ART 'Emotionally Freeing and Empowering'

Editor's pick
Contagion Live
7 October 2019
Injectable & long-acting HIV treatment

HIV implant targets disease for up to a year

Editor's pick
The Engineer
26 September 2019
PrEP science

Long-acting injectable multi-drug implant shows promise for HIV prevention and treatment

Editor's pick
EurekAlert
23 September 2019
Injectable & long-acting HIV treatment

DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product

Editor's pick
DURECT press release
6 August 2019
People with limited treatment options

Clinical and Economic Effects of Ibalizumab for Multidrug-Resistant HIV

Editor's pick
Infectious Disease Advisor
2 August 2019
Injectable & long-acting HIV treatment

ViiV Healthcare submits regulatory application to EMA for the first monthly, injectable treatment for HIV

Editor's pick
ViiV press release
30 July 2019
People with limited treatment options

EMA panel recommends ibalizumab for multidrug-resistant HIV-1

Editor's pick
Medscape (requires free registration)
30 July 2019
Injectable & long-acting PrEP

PrEP implant could last well over a year

News
24 July 2019
Injectable & long-acting HIV treatment

People with HIV express high satisfaction with monthly injectable regimen

News
23 July 2019
Injectable & long-acting HIV treatment

ViiV Healthcare announces start of first-ever study to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in clinical practice

Editor's pick
ViiV Healthcare press release
11 July 2019
Injectable & long-acting HIV treatment

Lyndra Therapeutics and Gilead Sciences to Collaborate on Development of Ultra-Long-Acting HIV Therapeutics

Editor's pick
Lyndra Therapeutics press release
10 July 2019
Injectable & long-acting HIV treatment

Study Finds Long-Acting HIV Meds Are Acceptable to Many People, but Differences Exist Among Groups

Editor's pick
The Body Pro
25 June 2019
Injectable & long-acting HIV treatment

NIH Trial Evaluates Long-acting HIV Medication Unable to Adhere to Strict Daily Regimens

Editor's pick
National Institute of Allergy and Infectious Diseases
9 May 2019
Injectable & long-acting HIV treatment

ViiV Healthcare submits New Drug Application to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine

Editor's pick
ViiV press release
29 April 2019
Injectable & long-acting HIV treatment

Long-Acting HIV Treatment Is Coming. Our Health Care System Needs to Prepare

Editor's pick
The Body Pro
16 April 2019
Injectable & long-acting HIV treatment

Jose Arribas, MD, on the Challenges That Come With Long-Acting Injectables

Editor's pick
Contagion Live
15 April 2019
Treatment simplification strategies

Laura Waters, MD, FRCP: Can Two Drugs Tango?

Editor's pick
Contagion Live
12 March 2019
New & experimental HIV treatments

HIV capsid inhibitor may offer long-term viral suppression

News
11 March 2019
Injectable & long-acting HIV treatment

Long-acting injectable treatment maintains viral suppression

News
8 March 2019
Injectable & long-acting HIV treatment

Long-acting injectible antiretroviral trial begins

Editor's pick
Science Speaks
28 February 2019
Injectable & long-acting HIV treatment

Emerging options: Doctors and advocates discuss treatment and prevention breakthroughs on the horizon

Editor's pick
Positively Aware
30 January 2019
Injectable & long-acting PrEP

Removable PrEP implant produces high drug levels in rabbits; further studies planned

News
15 November 2018
Injectable & long-acting HIV treatment

ViiV’s Long-Acting Injectable HIV Regimen Boasts Good 3-Year Results

Editor's pick
Poz
5 November 2018